Blood-based biomarkers (BBMs) for Alzheimer’s disease (AD) are rapidly emerging as a potential new fluid biomarker tool to support the early detection of AD pathology and may soon become a routine part of clinical practice. This site has been developed to provide healthcare professionals with evidence-based resources that highlight the scientific validation of these biomarkers, along with expert guidance on practical considerations for their effective implementation in clinical practice.
Blood-based biomarkers (BBMs) for Alzheimer’s disease (AD) are rapidly emerging as a potential new fluid biomarker tool to support the early detection of AD pathology and may soon become a routine part of clinical practice. This site has been developed to provide healthcare professionals with evidence-based resources that highlight the scientific validation of these biomarkers, along with expert guidance on practical considerations for their effective implementation in clinical practice.
{{ promo.Title.slice(0, 160) }}
{{ promo.Title }}
Title of the activity : {{ promo.Title }}
Provider : {{ promo.Provider }}
Virtual Enduring : {{ promo.VirtualEnduring }}
{{ promo.Title.slice(0, 160) }}
{{ promo.Title}}
{{ truncateText(promo.Title, promo.Description, 160) }}
{{ promo.Title }}
{{ promo.Description }}
Clinical Trials
Clinical Trials
Eisai has numerous drug candidates in clinical development and is actively recruiting for trials in neurology.
Explore Clinical TrialsGrants
Grants
This website provides policies and procedures for the preparation and submission of requests for Medical Education Grants (ME) and Investigator-Initiated Studies (IIS).
Explore Eisai Grants Process